Letter: The ESSENCE of Precision in MASH—Strengthening Trial Design for Broader Applicability
Authors:
- 19 December 2024
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (3) , 593-594
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE TrialAlimentary Pharmacology & Therapeutics, 2024
- The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic reviewHepatology, 2023
- Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart AssociationArteriosclerosis, Thrombosis, and Vascular Biology, 2022
- Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunityNature Metabolism, 2021
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementJournal of Hepatology, 2020
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialThe Lancet, 2015